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To analyze effectiveness of atorvastatin 20mg on lipid profiles and 
adhesion molecule VCAM-1 in patient with diabetes dyslipidemia. An 
observational prospective cohort study was conducted from November 
2016 to March 2017. Patients who fulfilled the inclusion criteria were taken 
twice for their lipid profiles and VCAM-1 measurements (before initiation of 
study and after 6 weeks treatment of atorvastatin 20mg). There were                 
13 patients who met the inclusion criteria. The results of 13 patients             
showed that after 6 weeks of atorvastatin therapy, there was a 28%  
decrease in total cholesterol (t0=223.77±49.69, t1=160.92±24.69), 39% LDL 
decrease (t0=152.59±44.25, t1 =93±21.44), a decrease in TG 38.6% 
(t0=200.85±101.53, t1=123.30±62.77) and a statistically significant 
decrease in VCAM-1 7.47% (t0=729.59±208.06, t1=675.06±182.88). The 
results of the correlation test between total cholesterol and VCAM-1 
(p=0.185, r=0.268), LDL and VCAM-1 (p=0.127, r=0.307), TG and VCAM-1 
(p=0.198, r=0.261) showed no correlation. Based on the results of the study, 
it can be concluded that atorvastatin therapy can provide improvements in 
atherogenic factors such as decreased lipid profile  and VCAM-1, and there 
was no correlation between lipid profile and VCAM-1 in type 2 DM patients 
with dyslipidemia. 





Diabetes mellitus (DM) is a metabolic 
disorder disease characterized by hyperglycemia 
(Triplitt et al., 2014). The most common lipid 
pattern in people with type 2 diabetes consists of 
hypertriglyceridemia (hyper-TG), low high-density 
lipoprotein cholesterol (HDL-C), and relatively 
normal plasma concentrations of low-density 
lipoprotein cholesterol (LDL-C) (Hegele et al., 
2013). The condition of hyperglycemia and 
increased free fatty acids can cause endothelial 
damage, endothelial become more permeable, 
presence of reactive oxygen species (ROS), and 
increase adhesion molecules (George and Lyon, 
2010). One of the adhesion molecules which has 
increased is VCAM-1. VCAM-1 is a member of the 
protein of immunoglobulin superfamily which is 
the framework for the migration of leukocytes              
to subendothelial space. If this leukocyte migration  
not prevented will cause monocytes to maturate 
into macrophages and form foam cell and fatty 
streak that will cause atherosclerosis (Wang and 
Huo, 2010). 
Levels of soluble adhesion molecules              
have been shown to correlate with various 
cardiovascular risk factors including hyper-
cholesterolemia and or hypertriglyceride, 
decreased HDL, hypertension, DM, and smoking. In 
two prospective studies of patients with type 2 
diabetes, VCAM-1 became a strong predictor of 
cardiovascular mortality. VCAM-1 levels are also 
significantly associated with intima-media 
thickness, an index of early atherosclerotic (Wang 
and Huo, 2010). 
Atorvastatin is a class of lipid-lowering 
agent, HMG CoA reductase inhibitor. HMG CoA               
is  a precursor of mevalonate formation which is             
a synthesis  of cholesterol  (Malloy and Kane, 2012).  
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Atorvastatin also has a pleiotropic effect that can 
inhibit inflammation by inhibition of leukocytes by 
decreasing the expression of adhesion molecules, 
therefore the aim of this study was to analyze the 
effect of atorvastatin on lipid profile and pleiotropic 
effects as inhibition of inflammation.  
 
MATERIAL AND METHODS 
This study conducted a prospective 
observational design from November 2016 to 
March 2017 was approved by Ethics Committee of 
the the faculty of Medicine Airlangga University 
Surabaya. We included pastients aged 35-79 years 
who were diagnosed with diabetic dyslipidemia, 
HbA1c 8-13%, lipid profiles during initiation of LDL 
therapy >100mg/dL and / or TG>150 mg/dL, free 
or at least 2-3 weeks after acute inflammation, and 
have not received atorvastatin therapy previously. 
Patients with elevated liver function tests (>3x 
normal values), patients with severe renal failure, 
patients with nephrotic syndrome with 
dyslipidemia, and patients taking progestin 
hormones, corticosteroids, and antiretroviral drugs 
(protease inhibitor class) were excluded from the 
study. Blood measurements were performed on 
lipid profiles (total cholesterol,          LDL, and TG) 
and VCAM-1 before therapy of atorvastatin 20mg 
and after 6 weeks therapy. VCAM-1 were measured 
with ELISA method.  
Analysis data started with normality test 
with Saphiro Wilk test. A comparative hypothesis 
test was performed to determined the differences 
of lipid profiles and VCAM-1 before therapy (t0) and 
after therapy (t1) with paired sample T-test and 
Wilcoxon test. In addition, a correlation test was 
performed to determine the correlation between 
lipid profile and VCAM-1 by using spearman 
correlation test.  
  
RESULTS AND DISCUSSION 
The number of male and female patients is 
almost equal with the most age range in the middle 
age range (46-59 years) (Table I). Based on 
research conducted by Mihardja et al in Indonesia 
also shows that the prevalence of DM increases with 
age with the highest age range 45-55 years 
(Mihardja et al., 2014). HbA1c levels indicate 
uncontrolled sugar ranges (8-13%) and most 
patients are overweight (BMI 25-18kg/m2). 
Overweight and obesity are the most potent risk 
factors for DM (WHO, 2016). Three patients had 
comorbidities of hypertension and two patients 
with CHD. In a study conducted by Lastra (et al.) 
also found that hypertension was found in more 
than 50% of patients with DM and contributed 
significantly to micro and macrovascular 
complications in DM. The risk factor for 
cardiovascular disease is 4 times higher in DM 
patients with hypertension (Lastra et al., 2014). 
The NCEP-ATP III guidelines divided LDL 
and TG levels within the range that can be used as 
indicative references when lipid-lowering therapy 
may be given. When TG levels are within a 
borderline high range, LDL-C is the main 
therapeutic target. Similarly, when TG levels are in 
the high range, LDL-C is still a major therapeutic 
target. Add lipid-lowering drugs such as fibrates to 
help reduce them. Individuals with very high TG 
levels (>500mg/dL) are at risk for acute 
pancreatitis, therefore the primary target is the 
reduction of TG first with a low-fat diet, weight 
management and physical activity, and the use of 
fibrates or nicotinic acid. If TG levels reach <500 
mg/dl then it can be replaced again with LDL-
lowering therapy (NCEPATP III, 2002). 
Most patients had total cholesterol data in 
the range of borderline high (200-239mg/dL) are 
62% with an average of 223.77±49.69mg/dL, LDL 
in the borderline high range (130-159mg/dL) and 
high (160-189mg/dL) are 38% with an average            
of 152.59±44.25mg/dL, triglycerides in the optimal 
range (<150mg/dl) are 54% with mean 
200.85±101.53mg/dL, the patient's HDL level           
was mostly at the level of >40mg/dL (69%) with an 
average of 44.21±9.97mg/dL. Diabetes with 
dyslipemia is usually characterized by three 
conditions: high triglyceride concentrations, low 
HDL concentrations, and high small dense LDL 
concentrations (Chehade et al., 2013). The baseline 
HDL values of patients were different than in those 
where only 31% of patients had low HDL values 
(<40mg/dL) (Table II). 
It was found that after 6 weeks of treatment, 
there was a significant decrease in lipid profile 
(cholesterol, LDL, and TG) and VCAM-1 levels (p 
<0,05). These results are consistent with previous 
studies conducted by hogue et al., suggesting that 
the administration of atorvastatin 20mg for 6 
weeks potentially altering lipid profile and also 
reduce inflammation (lowering CRP levels), 
oxidation (lowering levels of ox-LDL), and 
monocyte adhesion (Lowering levels of sICAM-1, 
sVCAM-1, sEselectin) in DM patients with 
hypertriglyceride (Hogue et al., 2008) (Table III). 
Correlation test is conducted to know the 
relationship between lipid profile level and         
VCAM-1. VCAM-1 increase in DM patients has been 
reported in previous studies, which is related to the 
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severity of atherosclerotic disease (Fasching et al., 
1996). The result of correlation analysis between 
serum lipid profile level with serum VCAM-1 level 
(Figure 1, 2 and 3) showed no significant 
correlation (p>0.05). Another study from Hubel et 
al found that VCAM-1 correlated with LDL (r = 0.50, 
P<0.03), but did not show any association with  
other  lipid  components  (Hubel et al., 1998). While 
in the study in Indonesia showed only correlation in 
patients with type 2 diabetes showed a tendency of 
Table I. Baseline characteristic of patients 
 
Patient Characteristics 
Total Patients (N=13) 
x̅± SD (range) 
n % 
Gender Male 6 46% - 
Female 7 54% - 
Age 
36-45 years 1 8% 
54.84±6.70 46-59 years 10 77% 
60-74 years 2 15% 
HbA1c 8-10 % 7 54% 
10.75±1.68 
11-13 % 6 46% 
BMI 
18.5-24.9 kg/m2 5 38% 
26.79±5.11 25.0-29.0 kg/m2 6 46% 
>30 kg/m2 2 16% 
Comorbidities Hypertension 3 23% - 
CHD 2 15% - 
 
Table II. Baseline profil lipid pasien (t0) 
 
Levels of Lipid Profile 
t0 t1 
n % n % 
Total Cholesterol 
Desirable  (<200mg/dL) 3 23% 12 92% 
Borderline High (200-239mg/dL) 8 62% 1 8% 
High (≥240mg/dL) 2 15% - - 
LDL 
Optimal (<100mg/dL) 1 8% 9 69% 
Near optimal (100–129 mg/dL) 1 8% 3 23% 
Borderline high (130–159 mg/dL) 5 38% 1 8% 
High (160–189mg/dL) 5 38% - - 
Very high (≥190mg/dL) 1 8% - - 
TG 
Optimal (<150mg/dL) 7 54% 10 77% 
Near optimal (150–129mg/dL) - - - - 
Borderline high (200–499mg/dL) 6 46% 3 23% 
High (≥500mg/dL) - - - - 
HDL 
<40mg/dL 4 31% 3 23% 
>40mg/dL 9 69% 10 77% 
 
Table III. Average changes in lipid profile and VCAM-1 
 
Lipid Profiles 
Mean ± SD 
P 
t0 t1 
Total Cholesterol 223.77±49.69 (165-369) 160.92±24.69 (126-205) 0.002 
LDL 152.59±44,25 (79-266) 93±21.44  (60-136) 0.001 
TG 200.85±101.53 (103-377) 123.30±62.77 (68-246) 0.016 
VCAM-1 729.59±208.06 675.06±182.88 0.019 
 
Asri Wido Mukti 
Volume 30 Issue 2 (2019)   131 
elevated plasma VCAM-1 levels along with the 
increase of albuminuria (Wibisono et al., 2012). The 
limitation of this study is the relatively small sample 
size (13 patients), and the variation of lipid profiles 
among patients is very large because it is influenced 
by many factor. This can cause statistical results 
that are not meaningful. 
 
CONCLUSION 
Atorvastatin therapy is able to improved 
atherogenic factors such as decreased lipid              
profile   (total   cholesterol,   LDL, TG)  and  VCAM-1  
inflammatory markers in DM patients with 
dyslipidemia, and no correlation between lipid 
profile (total cholesterol, LDL, TG) and VCAM -1. 
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Figure 3. Correlation Between Trigliserida and VCAM-1 
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